Human-Derived ECM Hydrogels for Advanced Drug Discovery

FATRIXGEL offers an advanced solution to the predictive gap in drug discovery through human-derived decellularized adipose extracellular matrix (hDAM) hydrogels. Unlike traditional standards such as mouse-tumor-derived Matrigel, FATRIXGEL provides an authentic human biomimetic microenvironment with high reproducibility and consistent batch quality.

This technology significantly enhances cellular differentiation processes and increases the reliability of in-vitro disease models used in fields such as oncology, regenerative medicine, and neural engineering.

Targeting the rapidly growing Research Use Only (RUO) market, FATRIXGEL is available in multiple highly processable formats, including:

• Pregels for laboratory applications
• Bio-inks for 3D bioprinting
• Porous scaffolds for tissue engineering

The technology is supported by protected intellectual property and validated according to strict international purity standards, including DNA levels below 50 ng/mg and endotoxin levels under 10 EU/mL.

By enabling more predictive human-relevant models, FATRIXGEL helps reduce reliance on animal testing and lowers failure rates in clinical trials. This positions the technology as a scalable and impactful platform supporting the transition toward more efficient and personalized biomedical research.